Durbin- part of Uniphar Group

Silver Sponsor

Durbin is dedicated to improving patient access to unlicensed medicine worldwide. Committed to quality and integrity, Durbin delivers its services with a ‘can-do’ attitude. The company pioneered the first gene therapy expanded access program and are now the first supplier of a true cross-border access program for a cell-based therapy. Through its expanded access, direct import, on-demand, and aid & development arms, Durbin serves healthcare practitioners and patients in 160 countries. Durbin offers digital solutions and a strong stakeholder network – including underserved markets in South and Latin America, APAC, CIS/EEU, Africa, Asia Pacific, and the Middle East. Robust operational footprint of 400,000 sq. ft. of pharmaceutical warehouse space at 6 global sites, dedicated to improving speed and quality of access to medicine. We go above and beyond to compliantly deliver unlicensed medicines to patients on time.
Durbin is part of the Uniphar Group (LON: UPR), a publicly traded company with €1.8b revenue and presence in the US, EU, UK and the Nordic countries. Uniphar is expressly focussed on the specialist treatments and orphan drug markets on a global level.

Get Involved At World Orphan Drug Congress USA


To Sponsor Or Exhibit


Justin Franks
t/ +1 914 819 3506




To Speak


Claire Murphy
t/ +1 646 619 1784




Marketing & Press Opportunities


Taylor Post 
t/ +1 646 619 1785